Europe — EMA
Padlas (Vildagliptin)
Vildagliptin, the active ingredient in Padlas, is a dipeptidyl peptidase‑4 (D‑type inhibitor) presented as a 50 mg tablet for oral use. It helps improve blood glucose control in adults with type 2 diabetes mellitus.
Request sourcing
What is Vildagliptin?
Vildagliptin, the active ingredient in Padlas, is a dipeptidyl peptidase‑4 (D‑type inhibitor) presented as a 50 mg tablet for oral use. It helps improve blood glucose control in adults with type 2 diabetes mellitus. GNH USA supplies Padlas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Padlas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Vildagliptin used for?
Padlas (vildagliptin) acts on the incretin pathway to improve glycaemic control in type 2 diabetes. It is used in the following recognised indications: - Type 2 Diabetes Mellitus: Improves fasting and post‑prandial blood glucose levels when used with diet, exercise and other antidiabetic agents. - Combination Therapy with Metformin: Provides additional HbA1c reduction when added to metformin in patients inadequately controlled on metformin alone. - Combination Therapy with a Sulfonylurea: Enhances overall glycaemic control when combined with a sulfonyl‑honey -
What are the side effects of Vildagliptin?
Vildil…
